🔎 Trials Near Me

Domov › Malobuněčný rakovina plic › Massachusetts

Klinické štúdie Malobuněčný rakovina plic v štáte Massachusetts

22 štúdií pre Malobuněčný rakovina plic hľadá účastníkov v zariadeniach v štáte Massachusetts.

Mestá v štáte Massachusetts

Oficiálny text štúdie (anglicky)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 19 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06586957

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Tufts Medical Center, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06047379

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  • Dana-Farber Cancer Institute /ID# 279690, Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07365241

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

  • Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 až 100 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07006727

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT05983432

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

  • Dana Farber Cancer Institute ( Site 1105), Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06780137

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Boston
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07038343

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center, Burlington
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT06712355

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  • Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 až 100 · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT06726148

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT06095505

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Massachusetts General Hospital Cancer Center, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT05592626

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  • Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT06203210

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

  • Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 7. 2026 · NCT06931626

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • Beth Israel Deaconess Medical Center, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 7. 2026 · NCT06131840

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 7. 2026 · NCT05652686

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

  • Dana Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 26. 6. 2026 · NCT07149363

A Study of LY4175408 in Participants With Advanced Cancer

  • Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT07046923

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  • Tufts Medical Center, Boston
  • Lahey Hospital and Medical Center, Burlington
  • Lahey Medical Center-Peabody, Peabody
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 3. 2026 · NCT06769126

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Brigham and Women's Hospital, Boston
  • a 1 ďalších
Prebieha náborObservačná štúdia
Vek 15 a viac · Všetky pohlavia · Aktualizované 29. 10. 2025 · NCT05265429

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

  • Massachusetts General Hospital, Boston
  • Harvard School of Public Health, Boston
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 18 až 120 · Všetky pohlavia · Aktualizované 29. 11. 2024 · NCT00471978

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.